H.C. Wainwright initiated coverage on Poseida Therapeutics with a new price target
$PSTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
H.C. Wainwright initiated coverage of Poseida Therapeutics with a rating of Buy and set a new price target of $15.00